HQ: Seattle, WA, USACEO: Steve HarrHeadcount: 300+sana.com ↗
Funding Summary
Total Funding
$1B+
Latest Valuation
~$600M (public market cap)
About
Flagship Pioneering-backed company developing both ex vivo and in vivo cell engineering approaches. Hypoimmune technology creates universal donor cells, and fusogen platform delivers genetic cargo without viral vectors.